Anxiety-depressive disorders after COVID-19

2024

Full text Open access: Hybrid Metadata (CSL-JSON)
DOI 10.59598/me-2305-6045-2024-111-2-57-63
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

The 2019 coronavirus (COVID-19) pandemic has reached more than 194 million people as of July 26, 2021, and continues to spread worldwide. During the course of the long pandemic, evidence of damage to various organs and systems, such as the nervous system and parts of it, began to emerge. Oxidative stress is one of the main causes of neuronal dysfunction and death, mainly due to excessive formation of reactive oxygen species and depletion of antioxidant reserves. Oxidative stress is characterized by an imbalance between the production of reactive oxygen species (ROS) and antioxidant defense mechanisms of the body. This process is involved in the onset and development of many neurological diseases. In this review, we analyzed and summarized the results of studies showing the association of neurological diseases, such as stroke, Parkinson's disease, and other neurological diseases, with excessive formation of oxidative stress products. This article aims to provide an overview of the relationship between oxidative stress and a range of neurological conditions, shedding light on the underlying mechanisms and potential therapeutic implications. Objective of the study was to determine the level of anxiety-depressive disorders among patients who underwent COVID-19. 90 people were examined and selected according to inclusion and exclusion criteria. To assess higher nervous functions, we used the hospital scales HADS I, HADS II, Beck depression scale. To date, our study has not found a clear link between the virus in the body and anxiety-depressive manifestations in patients, which may suggest that the main cause of the disorders lies in the social aspects of the pandemic.